ArticleBMC cancer2018
Taxifolin, a natural flavonoid interacts with cell cycle regulators causes cell cycle arrest and causes tumor regression by activating Wnt/ β -catenin signaling pathway.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 105 citations in OpenAlex.
- A novel chassis for high-quality recombinant protein expression: apoptosis pathway engineering via multi-gene knockout and efficacy improvement of CHO cells.Journal of biological engineering · 2026Article
- Exploring the therapeutic potential of naturally occurring taxifolin, a dietary flavonoid: an updated comprehensive review.Frontiers in pharmacology · 2026Review
- Exploring the Protective Effects of Taxifolin in Cardiovascular Health: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Dujieqing decoction suppresses multiple myeloma growth by inhibiting the Wnt/β-catenin pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Enhancing Cellular Homeostasis: Targeted Botanical Compounds Boost Cellular Health Functions in Normal and Premature Aging Fibroblasts.Biomolecules · 2024Article
- Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential.Heliyon · 2024Review
- Article
- Retraction Note: Growth inhibition and apoptosis in colorectal cancer cells induced by vitamin D-Nanoemulsion (NVD): involvement of Wnt/β-catenin and other signal transduction pathways.Cell & bioscience · 2024Article
- The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Review
- Article
- Article
- Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hepatoprotective effect of taxifolin on cyclophosphamide-induced oxidative stress, inflammation, and apoptosis in mice: Involvement of Nrf2/HO-1 signaling.Biomolecules & biomedicine · 2023Article
- Article
- Metabolomics-Based Analysis of the Effects of Different Cultivation Strategies on Metabolites ofMetabolites · 2023Article
- Phenolic Phytochemicals for Prevention and Treatment of Colorectal Cancer: A Critical Evaluation of In Vivo Studies.Cancers · 2023Review
- Network pharmacology and bioinformatics to identify the molecular mechanisms of Gleditsiae Spina against colorectal cancer.Current research in toxicology · 2023Article
- Wnt/β-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer.Cancer management and research · 2023Review
- New Perspectives of Taxifolin in Neurodegenerative Diseases.Current neuropharmacology · 2023Review
Corrections and comments
- Retraction · 2025-10-16Concerns/Issues about Image · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Objections by Author(s) · Plagiarism of Image · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/B5A5F030806E13A67CF65BE980F5E7
- Retracted
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew approaches for the prevention of colon cancer perseveres an essential necessity. Though, resistance to existing chemo-preventive drugs is moderately predominant in colon carcinogenesis. Taxifolin (dihydroquercetin) is a flavononol, have shown virile biological activities against few cancers. The current study was designed to investigate and equate antitumor activity of Taxifolin (TAX) in colorectal cancer cell lines and in HCT116 xenograft model in a comprehensive approach.
methodsTwo human colorectal cancer cell lines HCT116 and HT29, were used. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazoliumbromide (MMT) protocol was performed to elucidate the impact of TAX and β- catenin inhibitor (FH535) on the viability of HCT116 and HT29 cell lines. Apoptosis /cell cycle assay was performed. Data interpretation was done with a FACScan (Becton Dickinson, NJ). About 1 × 10
resultsWe found that TAX induced cytotoxicity in colorectal cells in a dose-dependent manner and time dependent approach. Further, our data validated that administration of TAX to human colorectal cancer HCT116 and HT29 cells resulted in cell growth arrest, variation in molecules controlling cell cycle operative in the G2 phase of the cell cycle and apoptosis in a concentration dependent approach. Further our results concluded that TAX administration decreases expression of β-catenin gene, AKT gene and Survivin gene and protein expression in in vitro and in vivo.
conclusionOur findings proposed that targeting β-catenin gene may encourage the alterations of cell cycle and cell cycle regulators. Wnt/β-catenin signaling pathway possibly takes part in the genesis and progression of colorectal cancer cells through regulating cell cycle and the expression of cell cycle regulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.